Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Rhabdomyosarcoma 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Leukemia, Myelomonocytic, Juvenile 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Brain Stem Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 18Vincristine 13Filgrastim 13Doxorubicin 13Carboplatin 13Etoposide 12Granulocyte Colony-Stimulating Factor 10Isotretinoin 9Cisplatin 9Topotecan 8Peripheral Blood Stem Cell Transplantation 8sargramostim 7Melphalan 7Radiotherapy 6etoposide phosphate 5Thiotepa 5Polymerase Chain Reaction 5Platinum 5Magnetic Resonance Spectroscopy 4Irinotecan 4Immunohistochemistry 4Gene Expression Profiling 4Colony-Stimulating Factors 41,2-diaminocyclohexaneplatinum II citrate 4lorukafusp alfa 3dinutuximab 3Temozolomide 3Stem Cell Transplantation 3Specimen Handling 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neuroblastoma × GRN163L peptide × Clear all
NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Children's Oncology Group

Phase 2 Withdrawn
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡